The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMGP.L Regulatory News (MGP)

  • There is currently no data for MGP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Medica Group Plc

30 Jun 2023 14:38

Premier Miton Group Plc - Form 8.3 - Medica Group Plc

Premier Miton Group Plc - Form 8.3 - Medica Group Plc

PR Newswire

LONDON, United Kingdom, June 30

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

PREMIER MITON GROUP PLC

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

 The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

 Use a separate form for each offeror/offeree

Medica Group plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

 

(e) Date position held/dealing undertaken:

 For an opening position disclosure, state the latest practicable date prior to the disclosure

29/06/2023

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

 If it is a cash offer or possible cash offer, state "N/A"

No

 

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

Ords

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

2,857,913

2.32%

 

 

(2) Cash-settled derivatives:

 

 

 

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

 

 TOTAL:

2,857,913

2.32%

 

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

n/a

Details, including nature of the rights concerned and relevant percentages:

n/a

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

Ordinary shares

Sale

500,000

211

 

 

 

 

 

 

 

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

n/a

 

 

 

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

n/a

 

 

 

 

 

 

 

 

(ii) Exercise

 

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

n/a

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

n/a

 

 

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

30/06/2023

Contact name:

Helena Celica

Telephone number:

01483 400428

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.



Date   Source Headline
28th May 20213:27 pmRNSDirector/PDMR Shareholding
28th May 20212:43 pmRNSDirector/PDMR Shareholding
25th May 20217:00 amRNSPosting of Annual Report and Notice of AGM
11th May 20217:10 amRNSNon-Executive Director Change
11th May 20217:10 amRNSResults for the year ended 31 December 2020
20th Apr 20219:30 amRNSHolding(s) in Company
16th Apr 20219:47 amRNSHolding(s) in Company
29th Mar 202110:48 amRNSHolding(s) in Company
25th Mar 20218:05 amRNSCompletion of Acquisition & Director/PDMR Dealings
23rd Mar 20219:31 amRNSCorrection: Results of Fundraise and TVR
23rd Mar 20217:00 amRNSResults of Fundraise and Total Voting Rights
23rd Mar 20217:00 amRNSRe-release: Proposed acquisition of US-based RadMD
22nd Mar 20215:07 pmRNSProposed Fundraise to raise approximately £16m
22nd Mar 20215:07 pmRNSProposed acquisition of US-based RadMD
19th Mar 20217:00 amRNSMicrosoft Research’s Dr Junaid Bajwa joins as NED
22nd Feb 20217:00 amRNSMedica and Integral Diagnostics establish JV, MedX
11th Feb 202110:09 amRNSHolding(s) in Company
29th Jan 20219:02 amRNSHolding(s) in Company
26th Jan 20217:00 amRNSAppointment of Liberum as Joint Corporate Broker
21st Jan 20217:00 amRNSTrading Update
18th Jan 20217:00 amRNSDr. Robert Lavis appointed Group Medical Director
4th Dec 202011:57 amRNSDirector/PDMR Shareholding
2nd Dec 20209:31 amRNSDirector/PDMR Shareholding
1st Dec 20209:34 amRNSHolding(s) in Company
18th Nov 20204:41 pmRNSSecond Price Monitoring Extn
18th Nov 20204:36 pmRNSPrice Monitoring Extension
12th Nov 20207:00 amRNSDirector/PDMR Shareholding
11th Nov 202012:41 pmRNSHolding(s) in Company
10th Nov 20201:56 pmRNSHolding(s) in Company
6th Nov 20202:26 pmRNSHolding(s) in Company
5th Nov 20207:00 amRNSDirector/PDMR Shareholding
4th Nov 20207:00 amRNSMedica acquires Global Diagnostics Ireland
27th Oct 20209:20 amRNSHolding(s) in Company
22nd Oct 20209:41 amRNSHolding(s) in Company
16th Oct 202011:26 amRNSHolding(s) in Company
7th Oct 202012:34 pmRNSHolding(s) in Company
16th Sep 20201:07 pmRNSDeclaration of Dividend
14th Sep 20207:00 amRNSInterim results demonstrate resilient performance
9th Sep 202010:36 amRNSHolding(s) in Company
25th Aug 20204:41 pmRNSSecond Price Monitoring Extn
25th Aug 20204:36 pmRNSPrice Monitoring Extension
14th Aug 20209:56 amRNSHolding(s) in Company
21st Jul 202010:49 amRNSHolding(s) in Company
8th Jul 20207:00 amRNSTrading Update
11th Jun 20203:22 pmRNSDirector/PDMR Shareholding
1st Jun 20204:54 pmRNSIssue of Equity
28th May 202010:14 amRNSHolding(s) in Company
21st May 202012:55 pmRNSHolding(s) in Company
20th May 20204:25 pmRNSResult of AGM
20th May 20207:00 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.